A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Last Updated May 14, 2025
Want to learn how to participate in this trial?
80948543LYM1002
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 1 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).
CONDITIONS
- Lymphoma, Non-Hodgkin
ELIGIBILITY
Inclusion Criteria:
* Histologic documentation of diffuse large B-cell lymphoma (DLBCL), including high-grade B-cell lymphoma and DLBCL arising from indolent lymphoma. All participants must have received at least 2 prior lines of therapy
* Participants must have measurable diseas
DETAILS
LOCATIONS
| Country (4) | City or Province (10) | Status |
| Australia | Fitzroy St Vincents Hospital Melbourne |
RECRUITING
|
| Australia | North Ryde Macquarie University Hospital |
RECRUITING
|
| Spain | Barcelona Hosp. Clinic de Barcelona |
RECRUITING
|
| Spain | Madrid Hosp. Univ. 12 de Octubre |
RECRUITING
|
| Taiwan | Taichung China Medical University Hospital |
RECRUITING
|
| Taiwan | Taipei City National Taiwan University Hospital |
RECRUITING
|
| Australia | Concord Concord Hospital |
RECRUITING
|
| Spain | Barcelona Hosp Univ Vall D Hebron |
RECRUITING
|
| Spain | Madrid Hosp. Gral. Univ. Gregorio Maranon |
RECRUITING
|
| United Kingdom | Leicester University Hospitals Of Leicester Nhs Trust |
RECRUITING
|
-37.79839, 144.97833
-33.79677, 151.12436
41.38879, 2.15899
40.4165, -3.70256
24.1469, 120.6839
25.04776, 121.53185
-33.84722, 151.10381
41.38879, 2.15899
40.4165, -3.70256
52.6386, -1.13169
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.